Domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through Akt

Thrombosis and Haemostasis

Volumn 94, Issue 3, 2005, Pages 606-614

  Katkade, Vaibhav ^a   Soyombo, Abigail A ^a   Isordia Salas, Irma ^a   Bradford, Harlan N ^a   Gaughan, John P ^a   Colman, Robert W ^a   Panetti, Tracee S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; High molecular weight kininogen; Migration; Sphingosine I phosphate; Vascular endothelial growth factor

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3ALPHA; HIGH MOLECULAR WEIGHT KININOGEN; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECEPTOR ANTIBODY; SPHINGOSINE 1 PHOSPHATE; UROKINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BOVIDS; CELL MIGRATION; CELL STIMULATION; CELL STRUCTURE; CHEMOTAXIS; CONTROLLED STUDY; CULTURE VESSEL; ENDOTHELIUM CELL; FOCAL ADHESION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; SIGNAL TRANSDUCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; CATTLE; CELL MOVEMENT; CELLS, CULTURED; CHEMOTAXIS; CHROMONES; ENDOTHELIAL CELLS; FOCAL ADHESIONS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; LYSOPHOSPHOLIPIDS; MORPHOLINES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; SPHINGOSINE; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24944577562     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-12-0834     Document Type: Article

References (47)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
2. Auerbach W, Auerbach R. Angiogenesis inhibition: A review. Pharmac Ther 1994; 63: 265-311.
3. Follman J. Endogenous angiogenesis inhibitors. APMIS 2004; 112: 496-507.
4. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 190: 3819-43.
5. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004; 103: 4554-61.
6. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1427-33.
7. Colman RW, Jameson BA, Lin Y et al. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-50.
8. Song JS, Sainz IM, Cosenza SC et al. Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 2004; 104: 2065-72.
9. Cao DJ, Guo YL, Colman RW. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res 2004; 94: 1227-34.
10. Wang S, Hasham MG, Isordia-Salas I et al. Upregulation of Cdc2 and cyclin A during apoptosis of endothelial cells induced by cleaved high-molecular-weight kininogen. Am J Physiol Heart Circ Physiol 2003; 284: H1917-H1923.
11. Colman RW, Pixley RA, Najamunnisa S et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-7.
12. Zhang JC, Donate F, Qi X et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A 2002; 99: 12224-9.
13. Hasan AA, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A 1998; 95: 3615-20.
14. Joseph K, Ghebrehiwet B, Kaplan AP. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 1999; 92: 246-55.
15. Mahdi F, Shariat-Madar Z, Todd RF, III, et al. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001; 97: 2342-50.
16. Mahdi F, Shariat-Madar Z, Kuo A et al. Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor. J Biol Chem 2004; 279: 16621-8.
17. Panetti TS. Differential effects of sphingosine 1-phosphate and lysophosphatidic acid on endothelial cells. Biochim Biophys Acta 2002; 1582: 190-6.
18. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
19. Lee M-J, Thangada S, Claffey KP et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99: 301-12.
20. Kimura T, Watanabe T, Sato K et al. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 2000; 348 Pt 1: 71-6.
21. Kono M, Mi Y, Liu Y et al. The Sphingosine-1-phosphate Receptors S1P1, S1P2, and S1P3 Function Coordinately during Embryonic Angiogenesis. J Biol Chem 2004; 279: 29367-73.
22. Panetti TS, Nowlen JK, Mosher DF. Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration. Arterioscler Thromb Vasc Biol 2000; 20: 1013-9.
23. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999; 253: 117-30.
24. Hla T. Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat 2001; 64: 135-42.
25. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002; 90: 1243-50.
26. Rosig L, Badorff C, Holzmann Y et al. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 2002; 277: 9684-9.
27. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997; 272: 15442-51.
28. Panetti TS. Tyrosine phosphorylation of paxillin, FAK, and p130Cas: Effects on cell spreading and migration. Front Biosci 2002; 7: D143-D150.
29. Guo YL, Wang S, Cao DJ et al. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J Cell Biochem 2003; 89: 622-32.
30. Kunapuli SP, De la Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain. J Biol Chem 1993; 268: 2486-92.
31. Pace CN, Vajdos F, Fee L et al. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995; 4: 2411-23.
32. Gum R, Juarez J, Allgayer H et al. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 1998; 17: 213-25.
33. Zhang JC, Claffey K, Sakthivel R et al. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 2000; 14: 2589-600.
34. Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol 2000; 2: E231-E236.
35. Lee MJ, Thangada S, Paik JH et al. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell 2001; 8: 693-704.
36. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.
37. Panetti TS, Hannah DF, Avraamides C et al. Extracellular matrix molecules regulate endothelial cell migration stimulated by lysophosphatidic acid. J Thromb Haemost 2004; 2: 1645-56.
38. Eriksson K, Magnusson P, Dixelius J et al. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003; 536: 19-24.
39. Wajih N, Sane DC. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 2003; 101: 1857-63.
40. Sudhakar A, Sugimoto H, Yang C et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003; 100: 4766-71.
41. Argraves KM, Wilkerson BA, Argraves WS et al. Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis. J Biol Chem 2004; 279: 50580-90.
42. Chae SS, Paik JH, Furneaux H, Hla T. Requirement for sphingosine 1-phosphate receptor-1 intumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 2004; 114: 1082-9.
43. Yatomi Y, Ohmori T, Rile G et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000; 96: 3431-8.
44. Panetti TS, Chen H, Misenheimer TM et al. Endothelial cell mitogenesis induced by LPA: Inhibition by thrombospondins -1 and -2. J Lab Clin Med 1997; 129: 208-16.
45. Short SM, Talbott GA, Juliano RL. Integrin-mediated signaling events in human endothelial cells. Mol Biol Cell 1998; 9: 1969-80.
46. Goel HL, Dey CS. Insulin stimulates spreading of skeletal muscle cells involving the activation of focal adhesion kinase, phosphatidylinositol 3-kinase and extracellular signal regulated kinases. J Cell Physiol 2002; 193: 187-98.
47. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999; 274: 16349-54.